<?xml version='1.0' encoding='utf-8'?>
<document id="12975494"><sentence text="Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats."><entity charOffset="63-74" id="DDI-PubMed.12975494.s1.e0" text="alphaxalone" /><entity charOffset="79-88" id="DDI-PubMed.12975494.s1.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.12975494.s1.e0" e2="DDI-PubMed.12975494.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12975494.s1.e0" e2="DDI-PubMed.12975494.s1.e1" /></sentence><sentence text="The objective of the present investigation was to characterize the pharmacodynamic interaction between the synthetic neuroactive steroid alphaxalone and the benzodiazepine midazolam"><entity charOffset="137-148" id="DDI-PubMed.12975494.s2.e0" text="alphaxalone" /><entity charOffset="157-181" id="DDI-PubMed.12975494.s2.e1" text="benzodiazepine midazolam" /><pair ddi="false" e1="DDI-PubMed.12975494.s2.e0" e2="DDI-PubMed.12975494.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12975494.s2.e0" e2="DDI-PubMed.12975494.s2.e1" /></sentence><sentence text=" The time course of the electroencephalographic (EEG) effect (11" /><sentence text="5-30 Hz) was determined in rats in conjunction with plasma concentrations" /><sentence text=" Alphaxalone was administered as a continuous intravenous infusion of 0, 1"><entity charOffset="1-12" id="DDI-PubMed.12975494.s5.e0" text="Alphaxalone" /></sentence><sentence text="2, 2" /><sentence text="2, or 5" /><sentence text="2 mg over 360 min" /><sentence text=" Midazolam was administered as a 5-min intravenous bolus infusion of 4 mg"><entity charOffset="1-10" id="DDI-PubMed.12975494.s9.e0" text="Midazolam" /></sentence><sentence text="kg-1" /><sentence text=" The pharmacokinetic profiles of both drugs were described by a two-compartment model" /><sentence text=" No pharmacokinetic interaction was observed" /><sentence text=" The EEG effect versus time profiles of midazolam and alphaxalone, when administered separately and in combination, were modeled on the basis of the recently proposed mechanism-based pharmacokinetic/pharmacodynamic model for GABAA receptor modulators, which contains separate expressions to describe the drug-receptor interaction and the stimulus-response relationship"><entity charOffset="40-49" id="DDI-PubMed.12975494.s13.e0" text="midazolam" /><entity charOffset="54-65" id="DDI-PubMed.12975494.s13.e1" text="alphaxalone" /><pair ddi="false" e1="DDI-PubMed.12975494.s13.e0" e2="DDI-PubMed.12975494.s13.e0" /><pair ddi="false" e1="DDI-PubMed.12975494.s13.e0" e2="DDI-PubMed.12975494.s13.e1" /></sentence><sentence text=" The pharmacodynamic interaction between alphaxalone and midazolam was best characterized using an independent drug-drug interaction model without an expression for allosteric modulation of the effect of midazolam by alphaxalone"><entity charOffset="41-52" id="DDI-PubMed.12975494.s14.e0" text="alphaxalone" /><entity charOffset="57-66" id="DDI-PubMed.12975494.s14.e1" text="midazolam" /><entity charOffset="204-213" id="DDI-PubMed.12975494.s14.e2" text="midazolam" /><entity charOffset="217-228" id="DDI-PubMed.12975494.s14.e3" text="alphaxalone" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e0" e2="DDI-PubMed.12975494.s14.e0" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e0" e2="DDI-PubMed.12975494.s14.e1" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e0" e2="DDI-PubMed.12975494.s14.e2" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e0" e2="DDI-PubMed.12975494.s14.e3" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e1" e2="DDI-PubMed.12975494.s14.e1" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e1" e2="DDI-PubMed.12975494.s14.e2" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e1" e2="DDI-PubMed.12975494.s14.e3" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e2" e2="DDI-PubMed.12975494.s14.e2" /><pair ddi="false" e1="DDI-PubMed.12975494.s14.e2" e2="DDI-PubMed.12975494.s14.e3" /></sentence><sentence text=" The final model contained an exponential expression to account for acute functional adaptation to the EEG effect upon continuous infusion of alphaxalone"><entity charOffset="142-153" id="DDI-PubMed.12975494.s15.e0" text="alphaxalone" /></sentence><sentence text=" The mechanism-based analysis showed that this functional adaptation is best explained by a change in the system-specific stimulus-response relationship, rather than the drug-receptor activation process" /><sentence text=" It is concluded that the pharmacodynamic interaction between alphaxalone and midazolam in vivo is best described using an independent interaction model without allosteric modulation"><entity charOffset="62-73" id="DDI-PubMed.12975494.s17.e0" text="alphaxalone" /><entity charOffset="78-87" id="DDI-PubMed.12975494.s17.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.12975494.s17.e0" e2="DDI-PubMed.12975494.s17.e0" /><pair ddi="false" e1="DDI-PubMed.12975494.s17.e0" e2="DDI-PubMed.12975494.s17.e1" /></sentence><sentence text="" /></document>